1
Simultaneous immunization of cattle with FMD and live anthrax vaccines Alejandra Capozzo Head of the Applied Veterinary Immunology Lab. Institute of Virology, Buenos Aires. Argentina
In collaboration with: Universidad del Centro de la Provincia de Buenos Aires
2
Juan Lahore
Myrian Trotta
Nancy Cardoso
Osvaldo Melucci
María Catena
Fernando Fernández
Mariano Pérez Filgueira
Alejandra Capozzo
Authors
ARGENTINA
3
FMD IN ARGENTINA EPIDEMIOLOGICAL STATUS:
- Free with vaccination - Free without vaccination
OIL-based vaccines, local producers
Four strains: O1/Campos, A24/Cruzeiro, A/Arg/01 and C3 Indaial
VACCINATION CAMPAIGN: - Adults: once a year - Calves <2 years old: twice a year
4
FMD vaccination in Argentina
SCENARIO:
Compulsory and rigorously controlled FMD vaccination
campaign
Vaccine efficacy as well as surveillance of vaccine
immunity is performed by serology.
Antibody titers obtained with Liquid Phase Blocking ELISA (LPBE) have
been correlated to in vivo protection to assess vaccine potency and
herd immunity (EPP 75%).
5
Bovine anthrax: a global issue
Hyper-Endemic-epidemic
Endemic
Sporadic
Free
Unknown
6
Buenos Aires Province represents 32% of farming land and 28% of the livestock stock: 49% of the farms have had at least one outbreak of bovine Bacillus Anthracis between 1977 and 2013
Bovine Anthrax
Buenos Aires Province
1977-2013
7
Vaccination against bovine anthrax
Sterne-strain live anthrax vaccine
Applied exclusively to adult animals
Boosters needed annually
Adult cattle population has received at least three FMD vaccinations
8
Why to combine vaccination schedules?
FMD-vaccines are applied to the whole cattle population on fixed schedules
The combination or co-administration of vaccines together with the FMD vaccine appears as a practical and efficient option for immunizing livestock, as long as this practice does not interfere with the immunogenicity conferred by those vaccines applied.
9
Combining FMD with other vaccines: background
• Immunization of young calves (sc) against FMD and against infectious bovine IBR- adhenovirus/PI-3 (in) did not interfere with the serological response against the FMD (de Clercq et al., 1989).
• Interference between FMD-V and a VSV-live vaccine (Castaneda et al., 1976).
The simultaneous application of FMD vaccines, particularly with live vaccines, needs to be
evaluated.
10
Experimental design
n=16 n=16 LPB-ELISA titers:
3.97 – 3.96
FMD-V FMD-V + ABV (each side of the neck)
Serum samples obtained at 0, 25, 55 and 90 days post-vaccination
SAFETY FIRST! no adverse effects were observed along the whole experiment
11
Current and novel assays
Aimed to evaluate different parameters of anti FMDV specific Abs
NAME INFORMATION
LPB-ELISA Total Abs
VNT Neutralizing Abs
Avidity ELISA Avidity index of Abs
IgG1 ELISA IgG1 titer
IgG1/IgG2 ELISA Ratio between IgG1 and IgG2
CURRENT
NOVEL
12
Total specific antibodies FMD-V
0 25 50 75 1002
3
4
5
* #* #
#
DPV
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
&#
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABV
0 25 50 75 1002
3
4
5
* #* #
#
DPV
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
&#
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABVFMD-V + ABV
0 25 50 75 1002
3
4
5
* # * ##
DPV
LP
B-E
LIS
A t
iter
(O1
Cam
po
s)
0 25 50 75 1002
3
4
5
& *
DPV
LP
B-E
LIS
A t
iter
(A24
/Cru
zeir
o)
FMD-vaccine alone FMD + ABV
0 25 50 75 1000
20
40
60
80
100* *
DPV
AI %
(O1
Cam
po
s)
A
B
C
EPP=75%
EPP=75%
O1/Campos
A24/Cruzeiro 25 DPV
26/11/13 21/12/130
2
4
6p=0.0109
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
26/11/13 21/12/130
2
4
6p=0.004
26/11/13 21/12/130
2
4
6p=0.168
0 25
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
26/11/13 21/12/130
2
4
6p=0.003
0 25
DPV
A
B
C
D
FMD-V FMD-V + ABV
13
0 25 50 75 1002
3
4
5
* # * ##
DPV
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
& *
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABV
0 25 50 75 1000
20
40
60
80
100* *
DPV
AI %
(O1 C
am
po
s)
A
B
C
EPP=75%
EPP=75%
Total specific antibodies FMD-V
0 25 50 75 1002
3
4
5
* #* #
#
DPV
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
&#
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABV
0 25 50 75 1002
3
4
5
* #* #
#
DPV
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
&#
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABVFMD-V + ABV O1/Campos
A24/Cruzeiro 28/02/14 21/12/13
0
2
4
6p=0.019
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
FMD-V FMD-V+
BAV
25 DPV
14
Avidity of specific antibodies
0 25 50 75 1000
20
40
60
80
100
DPV
AI %
(O1/C
am
po
s)
0 25 50 75 1000
20
40
60
80
100
DPV
AI %
(A24/C
ruzeir
o)
FMD-V
0 25 50 75 1002
3
4
5
* #* #
#
DPV
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
&#
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABV
0 25 50 75 1002
3
4
5
* #* #
#
DPVL
PB
-EL
ISA
tit
er
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
&#
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABVFMD-V + ABV
15
IgG isotypes induced by vaccination
0 25 50 75 1001
2
3
4
5
IgG
1 t
iter
FMD-V FMD-V + ABV0
1
2
3
4
5
IgG
1 t
ite
r (2
5 d
pv
)
0 25 50 75 1001
2
3
4
5
6
DPV
IgG
2 t
iter
FMD-V FMD-V + ABV0
1
2
3
4
5
6p=0.035
Vaccine
IgG
2 t
ite
r (2
5 d
pv
)
A B
C D
FMD-V
0 25 50 75 1002
3
4
5
* #* #
#
DPV
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
&#
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABV
0 25 50 75 1002
3
4
5
* #* #
#
DPV
LP
B-E
LIS
A t
iter
(O1 C
am
po
s)
0 25 50 75 1002
3
4
5
&#
DPV
LP
B-E
LIS
A t
iter
(A24/C
ruzeir
o)
FMD-vaccine alone FMD + ABVFMD-V + ABV
IgG1
IgG2
25 DPV
16
CONCLUSIONS
The Sterne-strain live anthrax vaccine can be co-administered with an oil-based tetravalent FMD vaccine in adult cattle, producing no impact in the humoral responses against FMDV booster responses.
This is the first study on the FMD responses elicited in cattle simultaneously immunized with FMD and anthrax vaccines.
The information provided here can be particularly useful in endemic regions with compulsory FMD vaccine programs
17
Beef comsuption in Argentina is over 60 Kg/person/year
THANK YOUThe Applied Veterinary Immunology Lab.
INTA- Buenos Aires, ARGENTINA
FMD
